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AbSTrACT
Malignant breast tumors are the most common tumors in humans and are associated with a poor prognosis. An 
accurate animal model of human mammary gland tumorigenesis is needed to test novel diagnosis and treatment 
strategies. Dogs represent a promising model since they develop such tumors spontaneously. In the present study, 
three immunomarkers, including calretinin, c-Kit (CD117) and placental alkaline phosphatase (Plap), were used 
and compared with each other, in relation to estrogen and progesterone receptors and HER2 (triple markers), 
with the intention of malignancy grading. Enhanced expression of calretinin and placental alkaline phosphatase, 
without immunoreaction to c-Kit in neoplastic cells, is related to high-grade malignancy. Out of 50 tumors, 31 were 
metastasized, 29 of which (93.5%) were moderately to strongly calretinin positive (P<0.05). However, the results for 
c-Kit - and Plap+ in metastatic tumors were not reproducible. It may be concluded that calretinin could be introduced 
as a determinant biomarker in the diagnosis of breast cancer metastasis.
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are prognostic and predictive in evaluation and 
management of malignant canine mammary tumors 
(CMTs) and human breast cancer (ONITIL et al., 
2009).
introduction
It has been well established that estrogen 
receptor (ER) expression, along with progesterone 
receptor (PR) and epidermal growth factor receptor 
2 (HER2), which are known as the triple markers, 
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Nevertheless, some tumors have no response 
to any of these immunohistochemical markers, 
and therefore, employing other markers to 
unveil concealed cancer profiles is unavoidable 
(TALIANO et al., 2013). 
In light of recent studies, many biomarkers have 
frequently been used to assess the tumor-grading 
score as a novel standard.
In the present research, three immunomarkers, 
including c-Kit (CD117), calretinin, and placental 
alkaline phosphatase (Plap) were used on tissue 
samples, to be compared with the triple markers that 
may be considered as practical tools in delineation 
of cutoff values between normal, benign, and 
malignant conditions.
With functions including proliferation, 
migration, and survival of hematopoietic stem cells, 
melanoblasts, primordial germ cells, endothelial, 
epithelial and endocrine cells, c-Kit proto-oncogene 
may be expressed in different tissues. It is postulated 
that the c-Kit gene plays a mysterious role in several 
diseases, with gain-of-function mutations including 
mastocytoma, gastrointestinal stromal tumors, 
and glial tumors, besides the loss of function and 
mutations associated with breast cancer (BERNEX 
et al., 1996; MAFFINI et al., 2008; MAHZOUNI 
and JAFARI, 2012). 
Calretinin is a 29-KD calcium binding protein, 
primarily expressed in neuronal cells. However, it 
can be tracked in other normal or neoplastic cells 
(LUGLI et al., 2003; ROGERS 1987; TALIANO et 
al., 2013). The main application of this protein is to 
distinguish mesothelioma from poorly differentiated 
pulmonary adenocarcinomas, but this marker may 
also be expressed in other malignant tumors affecting 
ovaries, testes, adrenal glands, the colon, breasts, the 
thymus, skin, and soft tissue (LUGLI et al., 2003; 
POWELL et al., 2011; TALIANO et al., 2013). 
Located in certain polarized epithelial cell 
types, placental alkaline phosphatases are glycosyl 
phosphatidylinositol-lipid anchored membrane 
proteins, with wide substrate specificity (FISHMAN 
1987, HARRIS 1990), producing an organic radical 
and inorganic phosphate in an alkaline medium 
as a catalyzer, by hydrolysis of phosphate esters 
(REICHLING and KAPLAN, 1988). Several 
isoenzymes of ALP are detected in specific organs. 
These enzymes are derived from the liver, bones, 
kidneys, placenta, intestines, and leukocytes 
(FRIEDMAN et al., 1996).
Diagnosis of a variety of diseases is related 
to serum ALP elevation, and it is a reliable 
and specific marker for some complications, 
including biliary cirrhosis, sclerosing cholangitis, 
hepatic lymphoma, breast cancer, and sarcoidosis 
(NEUSCHWANDER- TETRI, 1995). 
Although remarkable achievements, such 
as molecular assays, are characterized as high 
standards for classification of breast cancer (for 
example, c-Kit is a receptor tyrosine kinase (RTK) 
encoded by the KIT gene, and its mutations have 
recently been evaluated (KOLTAI et al., 2018) or in 
an earlier study (KUBO et al., 1998), as traditional 
test), Immunohistochemistry (IHC) is more 
available and reliable than other methods (PARISE 
and CAGGIANO, 2014). 
Materials and methods
Sample size. Fifty formalin fixed samples of 
primarily surgically excised malignant mammary 
tumors were collected from dogs, hospitalized at 
the Small Animal Teaching Hospital, University 
of Tehran, private veterinary hospitals and the 
veterinary clinic of Lorestan University. Of these, 31 
tumors had metastasized to the regional lymph nodes 
or distant organs, as diagnosed by FNA, imaging 
techniques, surgery, and in necropsy findings 
(Table 1) and the malignancy of the remainder was 
confirmed according to histopathological profiles 
(therefore, all were grade 3). Moreover, 29 of the 
tissue specimens were identified as malignant 
(including 17 metastatic and 12 non-metastatic 
specimens) by the auxiliary method of MALDI-
TOF, mass spectrometry prior to histopathological 
evaluation (ZAMANI-AHMADMAHMUDI et al., 
2014). 
Histopathology. The histopathological typing 
and grading of malignant neoplasms in the current 
research were carefully classified according 
to the new classification system proposed by 
GOLDSCHMIDT et al., 2011, depicted in Table 1. 
It is noteworthy that several cases were found to 
have two or more histological patterns.
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Table 1. Histopathological pattern and score staining of immunomarkers in patients
MetastasisPlapc-KitCalHer-2PrEr PatternNo.
LN, Liver102100Papillary cystic + ductal carcinoma + anaplastic carcinoma1
LN202000Solid carcinoma2





Lung, Spleen002000Tubular carcinoma with interlobular fibrosis8
LN, Lung002000Tubular carcinoma9















Lung103300Intraductal papillary carcinoma to tubulopapillary carcinoma21
LN, Lung003310
Micropapillary carcinoma + 
intraductal papillary carcinoma + 
solid adenosquamous
22
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-0 00000Solid + intraductal carcinoma37













Er, estrogen; Pr, progesterone; Her-2, human epidermal growth factor receptor-2; Cal, calretinin; Plap, placental alkaline 
phosphatase; ND, not defined; LN, lymph node
Table 2. Antibody specifications and pattern of staining
Antibody Clone Dilution Time of incubation Pattern of staining
ER monoclonal 1D5 1:100 80 min Nuclear
PR monoclonal PgR 636 1:100 80 min Nuclear
HER2 monoclonal PN2A 1:100 overnight at 4 °C Membranous
c-Kit polyclonal A4502  Catalog no 1:500 80 min
Cytoplasmic with membranous 
accentuation
Calretinin monoclonal DAK-Calret1 1:50 overnight at 4 °C Nuclear, cytoplasmic
PLAP monoclonal 8A9 1:50 80 min Membranous cytoplasmic
Table 1. Histopathological pattern and score staining of immunomarkers in patients (continued)
Immunohistochemical procedure. Paraffin- 
embedded blocks of each tumor were used to prepare 
4 µm-thick consecutive sections. The sections 
were then deparaffinized in xylene and rehydrated. 
Endogenous peroxidase was blocked by immersion 
in 0.3% H2O2 for 20 minutes. For antigen retrieval, 
the slides were incubated with Tris-EDTA (pH=9) 
for 15 minutes in an oven. In the next step, the slides 
were covered by primary antibodies for ER (clone 
ID5, Dako, Glostrup, Denmark, Cat No. M7047) 
at a dilution of 1:100, PR (clone PgR 636; Dako; 
M3569 1:100) HER2-pY-1248 (Phosphorylation 
site specific) (clone PN2A, Dako; 1:100), c-Kit 
(A4502, Dako; 1:500), Calretinin (clone DAK-
Calret1, Dako; M7245, 1:50) and Plap (clone 8A9, 
Dako; MA5-14064, 1:50) followed by incubation 
with a Dako REAL™ EnVision Detection System 
K5007. All the slides were then covered by 0.05% 
diaminobenzidine dihydrocloride solution (DAB), 
used as a chromogen, for 10 minutes, at ambient 
temperature. Antibody specifications and staining 
patterns are presented in Table 2. 
O. Dezfoulian et al.: Calretinin expression as a risk biomarker for metastatic canine mammary carcinoma
Vet. arhiv 90 (5), 453-466, 2020 457
Control samples. Positive and negative controls 
were included whenever possible to monitor the 
correct performance of the processed tissues. 
Positive internal control samples were selected 
from tumor blocks containing normal and non-
neoplastic tissue. The external positive control 
samples are depicted in Table 3. For negative 
controls, homologous nonimmune serum or buffer 
replaced the primary antibodies.
Scoring and statistical analysis. The scoring 
system was almost the same as the Quick score by 
PENA et al. (2014). 
It was modified for the percentage of cells 
labeled (no labeling = -/+, labeling ≤10% = +, 10 
up to 50% = ++, and more than 50% = +++), the 
score for intensity (absent = -, weak =+, moderate 
=++, and strong = +++). Only 2+ and 3+ for HER2 
overexpression were determined as criteria, and 
+1 was excluded on the basis of the description by 
ORDAS et al. (2007). 
Statistical analyses were performed by SPSS 
Version 19.0. The data were described as absolute 
and relative frequencies. The data were analyzed by 
Chi-square and Fisher’s exact test. A P-value ≤0.05 
was considered statistically significant. 
results
The results of immunohistochemical analysis 
are presented in Table 1. Nuclear immuno-staining 
of epithelial cells and to a lesser extent, in stromal 
cells, were shown for ER and PR in normal samples. 
HER2 had positive membranous immunolabeling 
in tumor cells. 
Calretinin positive cells were shown in luminal 
type tumor structures as linear patterns, in which 
the immunolabled cells with both cytoplasmic and 
nuclear immunoexpression were located in the 
innermost layer adjacent to the basement membrane. 
However, few myoepithelial cells reacted to this 
marker (Fig. 1; A, B). Conversely, widespread 
intermingled staining of neoplastic cells in other 
tumor types did not follow the specified pattern 
(Fig. 1; C-F). Calretinin expression was negative 
in all normal and most benign breast tumors, and 
weakly expressed in the rest (Table 3). Diffuse and 
strong cytoplasmic immunostaining by c-Kit was 
observed in normal epithelium (Fig. 2; A, B), while 
focal cytoplasmic and membranous expression was 
defined in benign or malignant neoplastic cells. 
A similar staining pattern was also determined in 
tumor cells by Plap, with no positively stained cells 
in the control group (Fig. 3; A-D). 
Table 3. Histopathological pattern and score staining of immunomarkers in normal and benign mammary glands
No Pattern Er Pr Her-2 Cal c-Kit Plap
1 Normal 2 2 0 0 3 0
2 Normal 2 1 0 0 3 0
3 Normal 3 2 0 0 2 0
4 Normal 2 0 0 0 2 0
5 Normal 1 2 0 0 3 0
6 Solid adenoma 0 0 2 1 1 0
7 Complex adenoma 0 0 3 0 0 0
8 Lobular hyperplasia 0 0 2 0 1 0
9 Fibroadenoma 0 0 3 0 0 0
10 Benign mixed 0 0 2 0 0 0
11 Lobular hyperplasia 1 0 3 0 1 0
12 Ductal adenoma 0 0 2 1 0 0
Er, estrogen; Pr, progesterone; Her-2, human epidermal growth factor receptor-2; Cal, calretinin; Plap, placental alkaline 
phosphatase;
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Fig. 1. Calretinin immunostaining. 1A - Tubular carcinoma, dog No. 23. Linear pattern; 1B - Higher magnification 
of Fig. 1A ; Nuclear and cytoplasmic immunopositive in epithelial neoplastic cells; 1C - Complex carcinoma, 
dog No. 23. Diffuse immunostaining; 1D - Higher magnification of Fig. C. Both nuclear and cytoplasmic 
immunolabeling; 1E - Cribriform carcinoma, dog No. 25. Diffuse immunolabeling; 1F - Higher magnification of 
Fig.1 E. Both nuclear and cytoplasmic immunoexpression.
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Fig. 2. c-Kit immunostaining. Control mammary gland; 2A - Diffuse cytoplasmic immunolabeling; 2B - Higher 
magnification of Fig. 2A.
Fig. 3. Plap immunostaining. 3A - Cribriform-comedocarcinoma, dog No. 50. Cytoplasmic to membranous 
immuolabeling; 3B - Higher magnification of Fig. 3A; 3C - Solid carcinoma, dog No. 2; 3D. Higher magnification 
of Fig. 3C.
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The differences between calretinin+/metastasis 
and calretinin+/c-Kit -/Plap+/metastasis were 
statistically significant (P<0.05); however, there 
were no statistical differences between ER-/
calretinin+/metastasis, c-Kit -/metastasis and 
Plap+/metastasis (P>0.05). 
Also, authentication of calretinin was employed 
in five canine metastasized tissue samples, including 
two regional lymph nodes (case no. 30 and 47), two 
pulmonary, and one liver specimen, in which the 
neoplastic cells responded as they did in mammary 
tumors. 
Table 4 highlights the correlation of triple 
markers with calretinin, c-Kit, and Plap, as well 
as the possible contribution of each biomarker in 
malignant and metastatic breast cancers. 
Table 4. Evaluation of immunohistochemical expression 
of triple markers, calretinin, c-Kit and
Plap in metastatic patients
TotalGroup
5 (16.1)PLAP +c-Kit -Cal+ER-/PR-/HER2-
1 (3.2)PLAP +c-Kit +Cal+ER-/PR-/HER2-
6 (19.3)PLAP -c-Kit -Cal+ER-/PR-/HER2-
2 (6.4)PLAP -c-Kit +Cal+ER-/PR-/HER2-
1 (3.2)PLAP -c-Kit -Cal-ER-/PR-/HER2-
1 (3.2)PLAP +c-Kit -Cal-ER-/PR-/HER2-
2 (6.4)PLAP +c-Kit +Cal+ER-/PR-/HER2+
4 (12.9)PLAP +c-Kit -Cal+ER-/PR-/HER2+
2 (6.4)PLAP -c-Kit -Cal+ER-/PR-/HER2+
1 (3.2)PLAP -c-Kit -Cal+ER-/PR+/HER2-
1 (3.2)PLAP -c-Kit -Cal+ER-/PR+/HER2+
2 (6.4)PLAP -c-Kit -Cal+ER+/PR+/HER2+
1 (3.2)PLAP -c-Kit + Cal+ER+/PR-/HER2-
2 (6.4)PLAP +c-Kit - Cal+ER+/PR-/HER2+
31 (100)
 
With regard to Table 5, it may be understood 
that the highest number of metastases were in the 
groups of triple negative 16/31 (51.6%) and ER-/
PR-, HER2+ 8/31 (25.8%).
Table 5. The different states of triple markers (ER, 
PR, and HER2) and their correlation with calretinin in 
mammary gland metastases
TotalCal-Cal +Triple groups
16 (51.6)2 (6.45)14 (45.1)ER-/PR-/HER2-
8 (25.8)0 (0)8 (25.8)ER-/PR-/HER2+
7 (22.5)0 (0)7 (22.5)Others
31 (100)2 (6.45)29 (93.5)Total
Discussion
Alongside using triple markers, it might be 
necessary to optimize the exploitation of other 
markers in screening for and diagnosing breast 
cancer.
Recently, tumor markers have been developed 
in breast cancer research, due to their impact 
on prognosis, treatment, survival, and for their 
relationship to breast cancer subtypes (BAUER et 
al., 2007).
Determination of both ER and HER2 status in 
breast cancer is useful as prognostic and predictive 
factors, and this has become standard practice 
in the management of breast tumor (BAUER et 
al., 2007). HER2 positivity has a direct link with 
aggressive tumor behaviors (PENA et al., 2014), 
while PR is only prognostic (HEFTI et al., 2013). 
The importance of canine HER2 overexpression 
in breast tumors remains unclear; although 
some researchers believe that in dogs too HER2 
expression provides malignant conditions in breast 
tissue, but the average rate of its expression is a 
little above 30% in malignant tumors, and therefore 
it is not recognized as a reliable marker (AHREN 
et al., 1996; PENA et al., 2014). As shown in Table 
2, apart from normal breast tissues that were HER2 
negative, all benign tumors were moderately to 
strongly HER2 positive. RUNGSIPIPAT et al. 
(1999) in their study showed that compared to 19.1% 
of malignant tumors, half of 32 benign tumors were 
HER2 positive, therefore, its expression is higher 
in benign lesions than in malignant ones. Thus, a 
lower expression rate of HER2 is more probably 
associated with an unfavorable prognosis.
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The results from medical literature studies reveal 
that unlike in humans, hormone receptor levels are 
significantly lower in canine breast cancer, meaning 
that hormone independency is more apparent in 
dogs (RICKETTS et al., 1991; RUTTEMAN et 
al., 1988). It was concluded that canine ER and PR 
positivity were regularly lower than in normal breast 
tissue or benign lesions (RUTTEMAN et al., 1988). 
Therefore, it seems that elevation of ER and PR is 
directly related to pathological cell proliferation, 
and the expression of ER in normal human 
breast is favorable to breast cancer development 
(RICKETTS et al., 1991). Nevertheless, whereas 
in normal breast tissue and benign tumors, they are 
constant, in malignancy, canine ER and PR levels 
vary and tend to fall (RICKETTS et al., 1991; 
RUTTEMAN et al., 1988).While the expression 
of ER and PR in our normal dogs were consistent 
with literature, however lack of expressions were in 
conflict in benign tumors except one (case No.11, 
Table 3). 
PR receptor expression takes place in almost 
two-thirds of carcinomas (CHANG et al., 2009; 
GERALDS et al., 2000; GUIL-LUNA et al., 2014; 
MARTIN de LAS MULAS et al., 2005), where a 
simple epithelial-type carcinoma, with the lowest 
levels of expression, this sticking point covers all 
benign tumors (GUIL-LUNA et al., 2014).
Simple epithelial-type carcinomas display less 
insensible PR expression compared to complex 
or mixed subtypes, and there is an association 
between PR expression and malignancy of tumors 
(GUIL-LUNA et al., 2014; MILLANTA et al., 
2005). As in our results, PR was not expressed in 
most exclusively ER- (38/50; 76%) lesions defined 
as having worse prognosis; however, all these are 
unlike the lowest expression of PR in experiments 
even in well-differentiated tumors (MOUSER et al., 
2010). 
However, for more accurate determination of 
prognosis and survival rate, usually both ER/PR 
and triple markers have been sporadically analyzed 
together, as follows: ER+/PR+ breast cancers have 
the best prognosis, meanwhile patients with ER+/
PR- display a worse clinical condition and more 
aggressive subtypes of ER+ breast cancers (HEFTI 
et al., 2013). The ER-/PR- subtype is the worst 
in terms of its response to conventional drugs. 
There is verified documentary evidence that PR is 
controlled by ER; therefore, ER- is a measure for 
PR-. Furthermore, PR expression has no logical 
connection with ER in the prognosis of breast 
cancers, and most authors believe that ER-/PR+ is 
a false subtype, although it remains controversial 
(HEFTI et al., 2013). ER-/PR+, in different literature, 
accounts for between zero and seven percent of 
breast cancer (BARDOU et al., 2003; COLDITZ 
et al., 2004; DE MAEYER et al., 2008; HEFTI et 
al., 2013; NADJI et al., 2005). It must be counted 
as a distinct subtype, showing clinicopathological 
signs, and so has worse prognosis than both ER+/
PR+ and ER+/PR-, but better than an ER-/PR- 
patient. Nevertheless, the contingency of clinical 
signs is more similar to ER+ than ER-/PR- (CHAN 
et al., 2015; DE MAEYER et al. 2008; SHEN et al., 
2015). However, 3/50 (6%) of our tumors appeared 
as ER-/PR+, all of which were Calretinin positive, 
and although the PR stained weakly, we could not 
rule these out as an artifact after a repeated test 
for both ER and PR, which had the same results. 
Perhaps, as in humans, it meant that the dogs were 
juvenile or had a higher tumor grade profile (CHAN 
et al., 2015; DE MAEYER et al., 2008). 
If breast cancers are classified according to the 
triple markers, they provide valuable evidence 
for treatment policy. As a standard source, ER+/
PR+, HER2- is the most prevalent subtype, ER+/
PR+; HER2+ has good prognosis, while, both ER/
PR-, HER2+ and triple negative (ER/PR-, HER2-) 
usually have a poor response to chemo-drugs, with 
a reduction in life expectancy (ONITIL et al., 2009). 
Although calretinin is a particular biomarker of 
mesothelial cells broadly employed for malignant 
mesothelioma recognition, its expression is 
demonstrated in carcinomas, such as malignant 
breast tumors and sarcomas (LUGLI et al., 2003; 
TALIANO et al., 2013). Lung, salivary gland, 
ovary, stomach, and colon carcinomas have been 
studied for this marker (POWELL et al., 2011). 
Moreover, calretinin is a promising candidate for 
testicular tumor diagnosis (CAO et al., 2001).
In veterinary literature, this marker has been 
applied in normal and neoplastic canine testicles. 
Only leydig and sertoli cells reacted to calretinin in 
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normal testis; however, its expression was revealed 
in all varieties of testicular tumors on the basis 
of the priority order, including leydig cell tumor, 
seminoma, and sertoli cell tumor (CIAPUTA et al., 
2014; RADI and MILLER 2005). 
Canine oral lesions such as acanthomatous 
ameloblastoma (CAA) and oral squamous cell 
carcinoma (OSCC) has also been tested with 
calretinin, with a significant reaction of the OSCC 
(FULTON et al., 2014). 
A strong correlation between calretinin 
expression and metastasis was found first in this 
study (P<0.05). It is anticipated that calretinin 
plays an important role in epithelial- mesenchymal 
transition (EMT); therefore, with vimentin 
expression, these markers might be considered as 
metastatic potentiation indicators (HENNESSY et 
al., 2009; TALIANO et al., 2013; ZHANG et al., 
2012).
Well-differentiated and individual ER+ tumors 
are generally calretinin negative, and, conversely, 
tumors with stronger calretinin expression are high 
grade. ER- is often associated with poor prognosis 
(LUGLI et al., 2003; POWELL et al., 2011; 
TALIANO et al., 2013).
Currently, only a few sources are available in 
the veterinary literature about the role of Plap and 
its diagnostic value in diseases. For example, its 
elevation was noticed as a good indicator in some 
canine conditions such as hepatic and endocrine 
diseases, and osteopathy (MILNE 1985), but it has 
not been fully investigated in neoplasms. 
The expression of placental alkaline phosphatase 
was directly associated with some types of cancers 
in human (CHANG et al., 1994; FISHMAN 1987; 
LANGE et al., 1982) and its function was induced 
by progestin in ER+ breast cancer cell lines, and 
by estrogen in endometrial adenocarcinoma 
cells (CHANG et al., 2009; DI LORENZO et al., 
1993; DI LORENZO et al., 1991). Our results in 
this context are significantly different. According 
to Table 1, only 2/22 (9%) of cases followed this 
pattern (ER+/PR+ Plap+) and 3/22 (13.6%) were 
(ER+/PR- Plap+) while 17/22 (77%) were (ER-/
PR- Plap+) and Plap function might be affected by 
other factors apart from ER/PR. The production 
of this tumor marker is associated with an 
oncodevelopmental gene, sometimes detectable in 
low levels of normal human serum, but excessive 
expression is indicative of cancer (MOSSNER et 
al., 1984). In accordance with the literature data, 
Plap expression is demonstrated in 20% of breast 
carcinomas (22/50 [44%] in present data) and in 
75% of intestinal carcinomas, and is not traceable in 
normal breast tissue or benign tumors (MOSSNER 
et al., 1984).
Therefore, Plap might be considered a potential 
biomarker in the diagnosis of malignant breast 
tumors, exclusively on fixed tissue sections using 
the immunohistochemical method (MCDICKEN et 
al., 1983; MOSSNER et al., 1984; STIGBRAND et 
al., 1985). 
Plap was not recognized in this study in either 
normal or benign tumors, although it appeared in 
22 malignant cases, 15 of which were metastasized. 
Similar to others, it is not beyond possibility that 
Plap induction has a direct link with malignancy.
In normal epithelial breast cells, the c-Kit 
receptor is located in large amounts on the 
membrane or cytoplasm of ductal or alveolar 
structures (CHUI et al., 1996; MAFFINI et al., 
2008), but with cellular proliferation in benign 
lesions, its amount is impressively reduced and it is 
absolutely unrecognizable in poorly differentiated 
cells (MAFFINI et al., 2008; NATALI et al., 1992; 
ULIVI et al., 2004). As shown in Table 2, our results 
are fully in line with those of other researchers. 
C-Kit was decisively expressed in normal breast 
tissues and gradually reduced or completely 
absent in benign tumors. The evidence indicates 
that homoeostasis regulation and differentiation 
of normal mammary epithelial cells are taken up 
by c-Kit in a complex molecular network, and it 
achieves second place in maintenance of normal 
growth in glandular epithelial cells after β1 integrin 
(REGAN et al., 2012). Therefore, in the absence 
of c-Kit, malignancy process could develop 
(MAFFINI et al., 2008; NATALI et al., 1992). 
One of the original mechanisms that contributes to 
c-Kit receptor loss in normal cells and subsequently 
accumulation of malignancy characteristics, is 
probably related to tyrosine kinase inhibitors and 
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the reduction in c-Kit activity (MAFFINI et al., 
2008; SAMOSZUK and CORWIN 2003).
Surprisingly, in their study on canine breast 
cancer using real-time RT-PCR, KOLTAI et al. 
(2018) found that c-Kit mutation occurred in 13 
dogs with mammary gland carcinoma, measured 
with other tyrosine kinases markers (including; 
VEGF, VEGFR1, PDGFR1, EGFR and c-MET), 
and concluded that mRNA expression of c-Kit 
was significantly higher than in normal breasts. In 
a similar work on 11 dogs, c-Kit RT-PCR product 
was higher in all benign and malignant carcinomas; 
however, its expression was low in normal glands 
(KUBO et al., 1998).
This is inconsistent with the present study and 
other results. The discrepancy might be related to 
the methodology. For example, ULIVI et al. (2004) 
studied c-Kit and its ligand 
(SCF) in normal cells, in situ, and invasive breast 
cancers using immunohistochemistry for c-kit and 
SCF protein, and an in situ hybridization technique, 
as well as RT-PCR for mRNA expression.
Both protein and mRNA expression of c-Kit and 
SCF were high in normal glands, lower in in situ, 
and absent in invasive breast cancer in IHC and in 
situ hybridization. However, by RT-PCR mRNA 
expression, they were displayed in both normal and 
breast tumors.
The authors believed that the variable results were 
due to the application of different methodologies, 
and concluded that morphological methods are 
the most reliable and applicable for detection 
of c-Kit and SCF in normal and tumor cells. In 
another study, c-Kit was evaluated in normal, non-
metastatic, and metastatic breast cancer on the basis 
of its pattern as precursor of canine mast cell tumor 
(MCT) (SALVADOR et al., 2013). The results were 
unexpected and not in accordance with the (MCT) 
profile pattern. However, they had not pointed out 
score and the protein was expressed in all samples. 
In our results, 30.7% and 50% of normal internal 
glands were calretinin positive in those tumors with 
+2 and +3 intensity scoring, respectively ( p=0.3) 
using the independent t-test. It was 37.5% for Plap 
with intensity 2 and 100% negative for c-Kit, and 
score zero. Perhaps this means that upregulation 
of calretinin and Plap in some normal glands 
precedes or is concurrent with its expression in 
neoplastic epithelial cells, whereas gene knockout 
is uniformed in both normal and neoplastic cells 
for c-Kit. Therefore, it must be assumed that it is 
inappropriate to consider normal glands alongside 
malignant structures as an internal control, and for 
proper evaluation, we strongly recommend using 
normal external controls. 
Conclusion 
Calretinin could be very useful alone or in 
conjunction with ER, PR, and HER2 antibodies in 
identifying and prognosis of malignant mammary 
gland tumors, from normal or benign lesions. 
However, another marker such as c-Kit and Plap 
can also play a potential role in defining such 
differences. Although the ER- was not significant 
in metastatic tumors, it must still be considered 
that 24/31 of metastatic tumors (77.4%) were in the 
ER-/PR-/HER2+/- group which is not insignificant.
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Sažetak
Maligni tumori dojke najčešći su tumori u ljudi i povezani su s lošom prognozom. Da bi se testirali novi dijagnostički 
postupci i terapijske procedure u ljudi, potreban je prikladan životinjski model tumorogeneze mliječne žlijezde. Psi 
su potencijalno dobar model zbog spontanog razvoja ovakvih tumora. U ovom su istraživanju, s ciljem stupnjevanja 
malignosti, međusobno uspoređena tri imunomarkera, kalretinin, c-Kit (CD117) i placentalna alkalna fosfataza (Plap), 
a zatim su isti uspoređeni i s estrogenskim, progesteronskim te HER2 (trostrukim) markerima. Povećanje izražajnosti 
kalretinina i placentalne alkalne fosfataze, bez imunoreakcije na c-Kit u neoplastičnim stanicama povezano je s 
visokim stupnjem malignosti. Od 50 tumora, 31 je metastazirao, od kojih je 29 (93,5 %) bilo umjereno do izrazito 
pozitivno na kalretinin (P < 0,05). Doduše, rezultati za c-Ki ti Plap+ nisu bili ponovljivi. Zaključujemo da bi kalretinin 
mogao poslužiti kao biomarker u dijagnostici metatstatskog raka dojke.
ključne riječi: biomarker; tumor mliječne žlijezde u pasa; kalretinin; c-kit; placentalna alkalna fosfataza_____________________________________________________________________________________________
